Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Phase 3
Completed
- Conditions
- Gastric UlcersDuodenal Ulcers
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2014-02-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 642
- Registration Number
- NCT01452750
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 482
- Registration Number
- NCT01452711
Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 305
- Registration Number
- NCT01452776
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis
Phase 3
Completed
- Conditions
- Erosive Esophagitis
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 409
- Registration Number
- NCT01452698
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
Phase 3
Completed
- Conditions
- Gastric UlcersDuodenal Ulcers
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2014-01-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 621
- Registration Number
- NCT01452763
Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 372
- Registration Number
- NCT01452724
A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis
Phase 2
Completed
- Conditions
- Endometriosis
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 397
- Registration Number
- NCT01452685
Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids
Phase 2
Completed
- Conditions
- Uterine Fibroids
- Interventions
- Drug: TAK-385Drug: Placebo
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 216
- Registration Number
- NCT01452659
Long-term Study of TAK-875
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: TAK-875
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1222
- Registration Number
- NCT01433406
Open-label Study of TAK-875
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: TAK-875
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 333
- Registration Number
- NCT01433419
© Copyright 2025. All Rights Reserved by MedPath